Jaleh Fallah1, Brian I Rini2. 1. Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk CA60, Cleveland, OH, 44195, USA. 2. Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk CA60, Cleveland, OH, 44195, USA. rinib2@ccf.org.
Abstract
PURPOSE OF REVIEW: In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF inhibitors in the treatment of cancer will be reviewed. RECENT FINDINGS: The HIF signaling pathway is activated by tumor-induced hypoxia or by inactivating mutations of the VHL gene. HIF is a transcription factor which regulates the expression of genes involved in adjusting mechanisms to hypoxia such as angiogenesis or apoptosis as well as tumor growth, invasion, and metastasis. The HIF pathway has a key role in development of resistance to different treatment modalities and higher expression of the HIF molecule is associated with poor prognosis. Clinical studies of the HIF inhibitors in patients with advanced/refractory cancers suggest benefit and warrant further studies of the HIF inhibitors either as a single agent or in combination with other therapeutic agents.
PURPOSE OF REVIEW: In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF inhibitors in the treatment of cancer will be reviewed. RECENT FINDINGS: The HIF signaling pathway is activated by tumor-induced hypoxia or by inactivating mutations of the VHL gene. HIF is a transcription factor which regulates the expression of genes involved in adjusting mechanisms to hypoxia such as angiogenesis or apoptosis as well as tumor growth, invasion, and metastasis. The HIF pathway has a key role in development of resistance to different treatment modalities and higher expression of the HIF molecule is associated with poor prognosis. Clinical studies of the HIF inhibitors in patients with advanced/refractory cancers suggest benefit and warrant further studies of the HIF inhibitors either as a single agent or in combination with other therapeutic agents.
Authors: Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe Journal: Mol Cell Biol Date: 2005-07 Impact factor: 4.272
Authors: Matthew H Kulke; Jennifer A Chan; Jeffrey A Meyerhardt; Andrew X Zhu; Thomas A Abrams; Lawrence S Blaszkowsky; Eileen Regan; Carolyn Sidor; Charles S Fuchs Journal: Cancer Chemother Pharmacol Date: 2010-10-20 Impact factor: 3.333
Authors: Christopher R Garrett; Tanios S Bekaii-Saab; Theresa Ryan; George A Fisher; Sally Clive; Petr Kavan; Einat Shacham-Shmueli; Aby Buchbinder; Richard M Goldberg Journal: Cancer Date: 2013-09-16 Impact factor: 6.860
Authors: Nabendu Pore; Anjali K Gupta; George J Cerniglia; Zibin Jiang; Eric J Bernhard; Sydney M Evans; Cameron J Koch; Stephen M Hahn; Amit Maity Journal: Cancer Res Date: 2006-09-15 Impact factor: 12.701
Authors: Kelsie R S Doering; Xuanjin Cheng; Luke Milburn; Ramesh Ratnappan; Arjumand Ghazi; Dana L Miller; Stefan Taubert Journal: Elife Date: 2022-03-14 Impact factor: 8.140